{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:13:41Z","timestamp":1790115221039,"version":"4.0.1"},"reference-count":55,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 therapy on the mechanisms associated with accelerated atherogenesis in patients with inflammatory arthritis, including an improvement of insulin sensitivity. In this study, we aimed to determine for the first time whether the anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 monoclonal antibody adalimumab may improve insulin sensitivity in non\u2010diabetic patients with psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prospective study on a series of consecutive non\u2010diabetic patients with moderate to severe psoriasis seen at the Dermatology Division of Hospital Universitario Marques de Valdecilla (Northern Spain) who completed 6\u00a0months of therapy with adalimumab (80\u00a0mg at week 0 followed by 40\u00a0mg every other week, starting 1\u00a0week after the initial dose). Patients with chronic kidney disease, hypertension or body mass index\u00a0\u2265\u00a035\u00a0kg\/m<jats:sup>2<\/jats:sup>were excluded. Metabolic and clinical evaluation including assessment of insulin sensitivity using the Quantitative Insulin Sensitivity Check Index (<jats:styled-content style=\"fixed-case\">QUICKI<\/jats:styled-content>) was performed at the onset of the treatment (time 0) and at month 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010nine patients (52% women; 38.6\u00a0\u00b1\u00a010.7\u00a0years) with moderate to severe psoriasis [body surface area (<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>) 37.9\u00a0\u00b1\u00a016.3%], Psoriasis Area and Severity Index [(<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) 18.9\u00a0\u00b1\u00a07.8] were assessed. Statistically significant improvement (<jats:italic>P<\/jats:italic>=0.008) of insulin sensitivity was observed after 6\u00a0months of adalimumab therapy (<jats:styled-content style=\"fixed-case\">QUICKI<\/jats:styled-content>at time 0: 0.35\u00a0\u00b1\u00a00.04 vs. 0.37\u00a0\u00b1\u00a00.04 at month 6). Significant improvement of<jats:sc>erythrocyte<\/jats:sc>sedimentation rate, ultrasensitive C\u2010reactive protein,<jats:styled-content style=\"fixed-case\">BSA<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>, Nail Psoriasis Severity Index, physician global assessment and psoriatic arthritis screening and evaluation questionnaire was also observed at month 6 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 for each variable).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results support a beneficial effect of the anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 blockade on the mechanisms associated with accelerated atherogenesis in patients with psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12814","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T12:11:11Z","timestamp":1414584671000},"page":"1325-1330","source":"Crossref","is-referenced-by-count":69,"title":["Anti\u2010<scp>TNF<\/scp>\u2010\u03b1 therapy improves insulin sensitivity in non\u2010diabetic patients with psoriasis: a 6\u2010month prospective study"],"prefix":"10.1111","volume":"29","author":[{"given":"T.","family":"Pina","sequence":"first","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Armesto","sequence":"additional","affiliation":[{"name":"Dermatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lopez\u2010Mejias","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Genre","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ubilla","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Gonzalez\u2010Lopez","sequence":"additional","affiliation":[{"name":"Dermatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Gonzalez\u2010Vela","sequence":"additional","affiliation":[{"name":"Pathology Division Hospital Universitario Marques de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Corrales","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Blanco","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Garcia\u2010Unzueta","sequence":"additional","affiliation":[{"name":"Endocrinology Research Unit Medical Laboratory Department Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Hospital Universitario Marques de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Llorca","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Computational Biology School of Medicine University of Cantabria Santander Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Gonzalez\u2010Gay","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marques de Valdecilla IDIVAL Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.08.013"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20878"},{"key":"e_1_2_5_5_1","first-page":"S62","article-title":"Mortality in psoriatic arthritis","volume":"26","author":"Gladman DD","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_6_1","first-page":"S80","article-title":"Mortality in ankylosing spondylitis","volume":"26","author":"Zochling J","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1493"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.94"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr285"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.112"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835bcce1"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2330"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02260.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.040"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5015"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02310.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.03.028"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02936.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000101572.76273.60"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181c10773"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22884"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.004"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/710928"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08190.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0703-z"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.370"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.365"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05287.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/674265"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-7310(09)70821-X"},{"key":"e_1_2_5_32_1","volume-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia","year":"2006"},{"issue":"2","key":"e_1_2_5_33_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman SR","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.001"},{"key":"e_1_2_5_35_1","first-page":"573","article-title":"Validity, reliability and sensitivity to change properties of the psoriatic arthritis screening evaluation questionnaire","volume":"301","author":"Domingez PL","year":"2009","journal-title":"Arch Der Res"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:25:3:259"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200702000408"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1983.tb03750.x"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90005-1"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90064-4"},{"key":"e_1_2_5_43_1","first-page":"462","article-title":"The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis","volume":"29","author":"Dessein PH","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(99)00005-4"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5249.665"},{"key":"e_1_2_5_46_1","first-page":"309","article-title":"Short\u2010term adalimumab therapy improves endo\u2010thelial function in patients with rheumatoid arthritis refractory to infliximab","volume":"24","author":"Gonzalez\u2010Juanatey C","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20371"},{"key":"e_1_2_5_48_1","first-page":"1403","article-title":"Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis","volume":"30","author":"Dessein PH","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.2143\/AC.64.5.2042688"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.601641"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000603400608"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semarthrit.2003.09.011"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2502"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12144"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12814","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:33:14Z","timestamp":1746473594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/jdv.12814"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12814","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}